The therapeutic approach to breast cancer necessitates a personalized strategy that accounts for the patient’s unique profile, encompassing the tumor’s biological attributes, genomic expression signatures, estrogen and progesterone receptor status, HER2 amplification, tumor microenvironmental dynamics, the patient’s genetic predispositions, and lifestyle factors (1). Here, ERBB2 is linked to breast carcinoma.